"Guideline on immunogenicity assessment of monoclonal 5 antibodies intended for in vivo clinical use.", , 18 November 2010 (2010-11-18), XP055047257, Retrieved from the Internet: URL:http://www.ema.europa.eu/docs/en_GB/do cument_library/Scientific_guideline/2010/1 1/WC500099362.pdf [retrieved on 2012-12-10] (B1)

A.-M. STROTHMEYER ET AL: "Comparative analysis of predicted HLA binding of immunoglobulin idiotype sequences indicates T cell-mediated immunosurveillance in follicular lymphoma", BLOOD, vol. 116, no. 10, 3 June 2010 (2010-06-03) , pages 1734-1736, XP055047248, ISSN: 0006-4971, DOI: 10.1182/blood-2010-02-270199 (B1)

DEFFAR KHALISSA ET AL: "Nanobodies - the new concept in antibody engineering", AFRICAN JOURNAL OF BIOTECHNOLOGY, ACADEMIC PRESS, US, vol. 8, no. 12, 17 June 2009 (2009-06-17), pages 2645-2652, XP009136924, ISSN: 1684-5315 (B1)

Edward G Routledge: "Reshaping antibodies for therapy - 5. Prospects for producing non-immunogenic monoclonal antibodies", , 1 January 1996 (1996-01-01), XP55040855, Retrieved from the Internet: URL:http://www.path.cam.ac.uk/~mrc7/reshap ing/index.html [retrieved on 2012-10-12] (B1)

GIBBS W WAYT: "Nanobodies", SCIENTIFIC AMERICAN, SCIENTIFIC AMERICAN INC., NEW YORK, NY, US, vol. 293, no. 2, 1 August 2005 (2005-08-01), pages 78,79-83, XP009124411, ISSN: 0036-8733, DOI: 10.1038/SCIENTIFICAMERICAN0805-78 (B1)

HOLLIGER PHILIPP ET AL: "ENGINEERED ANTIBODY FRAGMENTS AND THE RISE OF SINGLE DOMAINS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 23, no. 9, 1 September 2005 (2005-09-01), pages 1126-1136, XP008076746, ISSN: 1087-0156, DOI: 10.1038/NBT1142 (B1)

Meena Subramanyam: "Immunogenicity Considerations for BiologicsImmunogenicity", , 1 January 2009 (2009-01-01), XP055047259, Retrieved from the Internet: URL:http://www.bioanalyse.org/slides/08S07 .pdf [retrieved on 2012-12-10] (B1)

PETER DURAND SKOTTRUP ET AL: "Diagnostic evaluation of a nanobody with picomolar affinity toward the protease RgpB from", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS INC, NEW YORK, vol. 415, no. 2, 11 April 2011 (2011-04-11), pages 158-167, XP028378085, ISSN: 0003-2697, DOI: 10.1016/J.AB.2011.04.015 [retrieved on 2011-04-20] (B1)

REVETS H ET AL: "NANOBODIES AS NOVEL AGENTS FOR CANCER THERAPY", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 5, no. 1, 1 January 2005 (2005-01-01) , pages 111-124, XP009076361, ISSN: 1471-2598, DOI: 10.1517/14712598.5.1.111 (B1)

S POELMANS: "Immunogenicity monitoring during preclinical development of Nanobodies : comparing assay formats and species matrices", THE AAPS JOURNAL, vol. 12, no. S1, 1 January 2010 (2010-01-01), XP055047269, (B1)

TROJAN ANDREAS ET AL: "Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 6, no. 6, 1 June 2000 (2000-06-01), pages 667-672, XP002441484, ISSN: 1078-8956, DOI: 10.1038/76243 (B1)

VASILII V KLIMOV: "Spontaneous emission of an atom in the presence of nanobodies", QUANTUM ELECTRONICS, TURPION LTD., LONDON, GB, vol. 31, no. 7, 1 January 2001 (2001-01-01), pages 569-586, XP009160370, ISSN: 1063-7818, DOI: 10.1070/QE2001V031N07ABEH002007 (B1)

WO-A1-2007/085814 (B1)

WO-A1-2012/042026 (B1)

WO-A2-2006/129843 (B1)

WO-A2-2010/042815 (B1)

WO-A2-2011/073954 (B1)

WO-A2-2013/024059 (B1)

A summary of the technical data by 2016 (B2)

Adlersberg, La Ricerca Clin.Lab. 6.191.1976 (B2)

BREZSKI et al.: Human anti-IgG hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J Immunol. 2008; 181: 3183-3192. (B2)

BREZSKI: The Origins, specificity and potential biological relevance of human anti-IgG hinge autoantibodies. The Scientific World Journal. 2011; 11:1153-1167. (B2)

CORDY et al.: Specificity of human anti-variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-a receptor 1. Clinical and Experimental Immunology.2015; 182:139-148. (B2)

CV Professor Huub Schellekens (B2)

DEFFAR et al.: Nanobodies - the new concept in antibody engineering; African Journal of Biotechnology; vol. 8, no. 12, 2009, pp. 2645-2652. (B2)

Declaration Professor Guus van Dongen (B2)

Declaration Professor Huub Scheliekens (B2)

Declaration Professor Huub Schellekens (B2)

Declaration Professor Kontermann (B2)

Experimental Report 2016, filed during the examination proceedings (B2)

Experimental report Dr. Marie-Ange Buyse (B2)

Expert opinion on 3D Modeling, Dr. Carlo Boutton (B2)

FLEISCHMANN et al.: D04: ACR/ARHP Scientific meeting, Chicago Wed 11 9 11, presentation 2630 "A multiple ascending dose/proof of concept study of ATN-103". (B2)

GIBBS W. Wayt: Nanobodies; Scientific American; vol. 293, no.2, 2005, pp. 78, 79-83. (B2)

Gorovits et al.: Pre-existing antibody: biotherapeutic modality-based review. AAPS J. 2016 Mar; 18(2): 311-20. (B2)

HOLLIGER et al.: Engineered antibody fragments and the rise of single domains; Nature Biotechnology, vol. 23, no. 9, 2005, pp. 1126-1136 (B2)

IUPHAR/BPS Guide to Pharmacology database excerpt for vobarilizumab (B2)

Illustration of the cloning technology of D7 (B2)

KLIMOV et al.: Spontaneous emission of an atom in the presence of nanobodies; Quantum Electroncis, vol. 31, no. 7, 2001, pp. 569-586. (B2)

KONTERMANN: Strategies to extend plasma half lives of recombinant antibodies. Biodrugs. 2009; 23: 93-109. (B2)

MUYLDERMANS: Single domain camel antibodies: current status. Rev Mol Biol. 2001; 74: 277-302. (B2)

NIEBA et al.: Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng. 1997 Apr; 10(4): 435-44. (B2)

POELMANS, S.: Immunogenicity monitoring during preclinical development of Nanobodies: comparing assay formats and species matrices. The AAPS Journal. Vol. 12: No. SI. 1 January 2010. (B2)

Priority 1: US 61/500,360 (B2)

Priority 2: US 61/500,464 (B2)

Priority 4 : US 61/541,368 (B2)

Priority 5: US 13/435,567 (B2)

Priority 6: WO 2012/175400 A1 (B2)

Proudfoot et al., 2018 (with supplemental material) (B2)

REVETS et al.: Nanobodies as novel agents for cancer therapy; Expert Opinion on Biological Therapy, vol. 5, no. 1, 2005, pp.111-124. (B2)

RIECHMANN & MUYLDERMANS: Single domain antibodies: comparison of camel VH and camelized human VH domains. J. Immunol Meth. 1999; 231: 25-38. (B2)

ROUTLEDGE, Edward G.: Reshaping antibodies for therapy - 5. Prospects for producing non-immunogenic monoclonal antibodies; 1996 (B2)

Rheumatology News Conference coverage June 2017 IL-6 nanobody vobarilizumab advances despite equivocal phase II data (B2)

SCHMIDT et al. Synthetic peptide approach for elucidating the points of natural auto-antibody reactivity to proteolytic fragments of human IgGs. Del Valle et al. (eds). Peptides for youth: the proceedings of the 20th American Peptide Symposium. 411 Springer Science + Business Media, LLC. 2009. (B2)

SHANKAR et al.: A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nature Biotechnology. 2,007 Mav; 25(5). (B2)

SKOTTRUP et al.: Diagnostic evaluation of a nanobody with picomolar affinity toward the protease RgpB from...; Analytical Biochemistry, vol. 415, no. 2, 2011, pp. .158-167. (B2)

Sequence alignment between Seq ID No. 37 of the patent and "GSK1995057 of D35 (B2)

Structure of VH/VL interaction region (B2)

The sequence listing of WO 2011/073954 (D17) (B2)

VAN SCHIE et al.: Cross-reactive and pre-existing antibodies to therapeutic antibodies - effects on treatment and immunogenicity. MAbs. 2015; 7(4): 662-71. (B2)

WELSCHOF et al.: The antigen binding domain of non-idiotypic human anti-F(ab*)2 autoantibodies: study of their interaction with IgG hinge region epitopes. Human Immunology. 1999; 60:282-290 (B2)

WO-A1-2006/122787 (B2)

WO-A1-2010/100135 (B2)

WO-A1-2012/131035 (B2)

WO-A1-2014/111550 (B2)

XUE et al.: Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of Pharmaceutical Scientists. AAPS J. 2013 Jul: 15(3): 852-5. (B2)